VRM
JAZZ icon

Vectors Research Management’s Jazz Pharmaceuticals JAZZ Stock Holding History

Vectors Research Management’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-2
Closed – – 302
2022
Q2 		$0 Hold
2
– – ﹤0.01% 517
2022
Q1 		$0 Hold
2
– – ﹤0.01% 509
2021
Q4 		$0 Hold
2
– – ﹤0.01% 604
2021
Q3 		$0 Hold
2
– – ﹤0.01% 492
2021
Q2 		$0 Buy
+2
New +$346 ﹤0.01% 502

Other funds holding JAZZ

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
PCM
Polaris Capital Management Boston, Massachusetts $1.22B AUM 26.01% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Vectors Research Management's JAZZ Position: Q3 2022 in Review

Vectors Research Management sold out of Jazz Pharmaceuticals (JAZZ) in Q3 2022, closing a stake of 2 shares.

Vectors Research Management first reported a position in JAZZ in Q2 2021 and held it in 5 quarters. The position peaked at $0 in Q2 2022. 468 funds tracked by Wall St. Rank hold JAZZ as of Q3 2022.

  • Vectors Research Management reported no remaining Jazz Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
  • Vectors Research Management sold 2 Jazz Pharmaceuticals shares in Q3 2022.
  • Vectors Research Management first reported a position in Jazz Pharmaceuticals in Q2 2021 and held it in 5 quarters.
  • Vectors Research Management's Jazz Pharmaceuticals position peaked at $0 in Q2 2022.
  • 468 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q3 2022.

Based on Vectors Research Management's 13F filing for Q3 2022, filed 8 Nov 2022.